Trending...
- Beyond Visionary Has Partnered With Heal America To Host INFORM Dallas
- Sea Island Writers Retreat and chromatic black™ Host Three Virtual Writing Workshops
- Help Wanted: Oakland-Based Children Rising Seeks Volunteers to Help Students Overcome COVID-Related Learning Loss
EMERYVILLE, Calif., Aug. 4, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and the Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF), today announced the discovery, functional characterization, and recovery of a patient-derived T cell receptor sequence against a cancer neoantigen.
Together, Berkeley Lights and JLF were able to measure and identify T cells that were reactive against peptides used in a cancer vaccine that was administered to a patient to successfully stimulate an immune response against their advanced-stage pancreatic cancer leading to complete remission. The patient was treated under the supervision of physicians at Washington University in St. Louis.
The unprecedented speed of these results relied on the Berkeley Lights Beacon® system. Applying the cell therapy development workflow, thousands of phenotypic measurements of single T cells were performed within one week. These measurements identified T cells that were cytotoxic and capable of secreting cytokines in response to antigen encounter, which were therefore predicted to be functional and subsequently sequenced at a single cell level. Cloning these T cell receptor sequences and expressing them in naïve T cells enabled functional validation against an antigen of interest. This function-first measurement capability of the Berkeley Lights platform is a significant differentiator compared to frequency-based assessments of TCRs which result in functional validation bottlenecks, adding to a growing number of highly differentiated service offerings at Berkeley Lights.
More on Missouriar
"This unique workflow combines Berkeley Lights' core strength of functional analysis of live cells, along with the use of the new Biofoundry services organization to help customers accelerate their therapeutic discoveries in a faster, more scalable way," said Siddhartha Kadia, Ph.D., chief executive officer of Berkeley Lights. "We look forward to continuing to work with JLF and their partners in evaluating immune response to cancer vaccines, mapping TCRs to neoantigens and ultimately supporting this important work to save patient lives."
The JLF has the mission of providing personalized neoantigen cancer vaccines for appropriate patients who have advanced cancers and seek compassionate use treatment.
"The data is exceedingly clear that, together, we have successfully identified a functional, patient- and antigen-specific TCR validating both our treatment methodology and the Berkeley Lights technology for personalized cancer vaccines compared to conventional approaches," said William Hoos, president of the Jaime Leandro Foundation for Therapeutic Cancer Vaccines. "This is an exciting advancement in our mission."
From the clinical team, Dr. William Gillanders, professor of surgery at Washington University School of Medicine, commented:
"The Berkeley Lights technology can take immune monitoring to the next level by evaluating multiple quantitative measurements of live cell behavior and recover that cell for molecular characterization. This is going to be tremendously useful for the field by providing a much deeper dataset to further understand cancer vaccines and predict clinical outcomes as well as to serve the growing need of combination therapies where TCR-T can be utilized."
More on Missouriar
1Daniel A King, Amber R Smith, Gino Pineda, et al. Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and organoid profiling. medRxiv 2021.12.16.21267326; doi: https://doi.org/10.1101/2021.12.16.21267326
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
Berkeley Lights' Beacon® and Lightning® systems and Culture Station™ instrument are FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.
SOURCE Berkeley Lights, Inc.
Together, Berkeley Lights and JLF were able to measure and identify T cells that were reactive against peptides used in a cancer vaccine that was administered to a patient to successfully stimulate an immune response against their advanced-stage pancreatic cancer leading to complete remission. The patient was treated under the supervision of physicians at Washington University in St. Louis.
The unprecedented speed of these results relied on the Berkeley Lights Beacon® system. Applying the cell therapy development workflow, thousands of phenotypic measurements of single T cells were performed within one week. These measurements identified T cells that were cytotoxic and capable of secreting cytokines in response to antigen encounter, which were therefore predicted to be functional and subsequently sequenced at a single cell level. Cloning these T cell receptor sequences and expressing them in naïve T cells enabled functional validation against an antigen of interest. This function-first measurement capability of the Berkeley Lights platform is a significant differentiator compared to frequency-based assessments of TCRs which result in functional validation bottlenecks, adding to a growing number of highly differentiated service offerings at Berkeley Lights.
More on Missouriar
- City of Columbia announces fire chief finalists
- Diedra Harrison-Greenaway launches new book titled: The Blueprint: A Guide Towards Cannabis Business Ownership
- Core & Main Completes Acquisition of Inland Water Works Supply Co.
- Springfield: Novavax COVID-19 Vaccine Event will be held on Aug 18
- Evolytics Ranks #58 on Fortune's 2022 List of Best Small Workplaces™
"This unique workflow combines Berkeley Lights' core strength of functional analysis of live cells, along with the use of the new Biofoundry services organization to help customers accelerate their therapeutic discoveries in a faster, more scalable way," said Siddhartha Kadia, Ph.D., chief executive officer of Berkeley Lights. "We look forward to continuing to work with JLF and their partners in evaluating immune response to cancer vaccines, mapping TCRs to neoantigens and ultimately supporting this important work to save patient lives."
The JLF has the mission of providing personalized neoantigen cancer vaccines for appropriate patients who have advanced cancers and seek compassionate use treatment.
"The data is exceedingly clear that, together, we have successfully identified a functional, patient- and antigen-specific TCR validating both our treatment methodology and the Berkeley Lights technology for personalized cancer vaccines compared to conventional approaches," said William Hoos, president of the Jaime Leandro Foundation for Therapeutic Cancer Vaccines. "This is an exciting advancement in our mission."
From the clinical team, Dr. William Gillanders, professor of surgery at Washington University School of Medicine, commented:
"The Berkeley Lights technology can take immune monitoring to the next level by evaluating multiple quantitative measurements of live cell behavior and recover that cell for molecular characterization. This is going to be tremendously useful for the field by providing a much deeper dataset to further understand cancer vaccines and predict clinical outcomes as well as to serve the growing need of combination therapies where TCR-T can be utilized."
More on Missouriar
- Distinguished New York Trial Attorney and Author Donates Book Proceeds to NYU Cancer Research Center
- Congratulations to Meade Summers, Hilliker Corp. President, Selected as "2022 Best Bosses in STL"
- Treat Yourself Right This Summer With LA's Best Massage Therapy for Serious Pain Relief Near You!
- Springfield: Local Continuum of Care issues Notice of Funding Opportunity for homeless services projects
- DEKALB® Brand Announces Partnership As Official Corn Seed of MLB at Field of Dreams
1Daniel A King, Amber R Smith, Gino Pineda, et al. Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and organoid profiling. medRxiv 2021.12.16.21267326; doi: https://doi.org/10.1101/2021.12.16.21267326
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
Berkeley Lights' Beacon® and Lightning® systems and Culture Station™ instrument are FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.
SOURCE Berkeley Lights, Inc.
Filed Under: Business
0 Comments
Latest on Missouriar
- VA Center of North County Hosts It's First Annual VANC Fest; an Art, Music and Culinary Experience
- Nino X Man releases Hip-Hop Compilation titled "662 the Truth" with No Limit Forever East
- St. Louis Municipal Courts Dismisses Backlog of Low-Level Cases as City of St. Louis Announces Date for Warrant Reset Day, Second Chance Job Fair
- 10 Years in the Making: #LatinaGeeks Celebrates 10th Anniversary with Inaugural Inspirada Awards & Fundraising Gala
- Missouri American Water Completes Acquisition of Eureka Water and Wastewater Systems, Plans for Pipeline Construction
- Kansas: Audit of the Short Term Rental Program Initiated
- Kansas: Community Policing and Prevention Fund Audit Initiated
- Kansas: City Auditor's Office Annual Report for Fiscal Year 2022
- 3i Solutions Announces New Leadership Brings a Customer-Focused Approach
- Columbia: Interested parties meeting for Greek Town sidewalk improvement project to be held Aug. 10
- Columbia: Lane closure due to road work scheduled for Aug. 8-11 on East Brown School Road
- Ann Marr Joins Board of Directors of Cass Information Systems, Inc.
- Caleres to Announce Second Quarter 2022 Results on August 23
- Help Wanted: Oakland-Based Children Rising Seeks Volunteers to Help Students Overcome COVID-Related Learning Loss
- MEDIA ALERT: Press conference Thursday to report out Prosper Springfield progress
- Multi-Agency Resource Center for Flood Survivors Announced for City of St. Louis
- Interested parties meeting for Phase 2 of new terminal project at Columbia Regional Airport scheduled for Aug. 10
- E3 Forensic Platform Innovates again with Remote Cloud Collection
- New Jewish Theatre Presents World Premiere of "The Bee Play" September 8-25